Combination Use of First-Line Afatinib and Proton-Pump Inhibitors Reduces Overall Survival Among Patients with EGFFR Mutant Lung Cancer

Combination Use of First-Line Afatinib and Proton-Pump Inhibitors Reduces Overall Survival Among Patients with EGFFR Mutant Lung Cancer

Meng-Chin Ho,1 Ying-Shan Chung,2,3 Yu-Ching Lin,1,4 Ming-Szu Hung,1,4,5 Yu-Hung Fang1,3 1Division of Thoracic Oncology, Department of Pulmonary and Critical Care Medicine, Chang Gung Memorial Hospital, Puzi City, Chiayi County, Taiwan, Republic of China; 2Department of Pharmacy, Chang Gung Memorial...

Full description

Bibliographic Details
Main Authors: Ho MC, Chung YS, Lin YC, Hung MS, Fang YH
Format: Article
Language:English
Published: Dove Medical Press 2022-12-01
Series:OncoTargets and Therapy
Subjects:
proton-pump inhibitor
epidermal growth factor receptor tyrosine kinase inhibitor
non-small cell lung cancer
afatinib
chang gung research database
Online Access:https://www.dovepress.com/combination-use-of-first-line-afatinib-and-proton-pump-inhibitors-redu-peer-reviewed-fulltext-article-OTT

Internet

https://www.dovepress.com/combination-use-of-first-line-afatinib-and-proton-pump-inhibitors-redu-peer-reviewed-fulltext-article-OTT

Similar Items